WHOLE GENOME DNA METHYLATION PROFILING WITH EPIGNOSTIX CLASSIFIER
The gold standard for glioblastoma diagnosis
WHOLE GENOME DNA METHYLATION PROFILING WITH EPIGNOSTIX CLASSIFIER
The gold standard for glioblastoma diagnosis
What is Whole Genome Methylation Profling
Whole Genome DNA Methylation Profiling with Epignostix Classifier is a powerful test that examines over 900,000 DNA sites across your tumor’s genome to reveal its unique epigenetic “fingerprint.” Using advanced machine learning your tumor is classified according to over 100 known brain tumor methylation classes. It is considered the most accurate method for diagnosing and classifying CNS tumors, ensuring your diagnosis is correct even when pathology is inconclusive or atypical.
WHY IT MATTERS FOR GLIOBLASTOMA PATIENTS
- Precisely distinguishes glioblastoma from other aggressive gliomas and non-glial tumors.
- Guides therapy by detecting MGMT promoter methylation, a key predictor of chemotherapy response.
- Maps chromosomal alterations like EGFR amplification, chromosome 7 gain/10 loss, and CDKN2A/B deletion.
- Identifies molecular features that confirm an IDH-wild type glioblastoma per WHO 2021 criteria.
- Reduces misdiagnosis and prevents inappropriate or ineffective treatment.
Guides treatment
Guides treatment decisions by detecting MGMT Methylation status, a key predictor of chemotherapy response.
Reduces Diagnostic Errors
Reduces misdiagnosis; ensures far fewer diagnostic errors than with relying on histopathology and appearance solely.
Clinical trials
Supports clinical trial enrollment based on molecular classification
classification of Tumors
Identifies glioblastoma subtypes that respond differently to therapy, influence clinical decision-making, and have prognostic significance.
Diagnostic accuracy
Ensures accurate diagnosis of glioblastoma and other CNS tumors.
In glioblastoma, identifying methylation class and subtype is now considered a standard-of-care diagnostic step under 2021 WHO guidelines.
"Getting this test helped confirm my patient’s diagnosis and helped guide more effective treatment."
- Provider, on Whole Genome Methylation Profiling
TEST INFORMATIOn
Feature
DETAILS
| Sample | 8-10 FFPE scrolls or 10-20 unstained slides with 1 H & E |
| Turnaround Time | 10-14 business days |
| CPT Code | 0020M |
| Insurance | Covered by Medicare and major insurers |
